GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Titan Pharmaceuticals Inc (NAS:TTNP) » Definitions » Shiller PE Ratio

TTNP (Titan Pharmaceuticals) Shiller PE Ratio : (As of Jan. 18, 2025)


View and export this data going back to 1996. Start your Free Trial

What is Titan Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Titan Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Titan Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Titan Pharmaceuticals Shiller PE Ratio Chart

Titan Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Titan Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Titan Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Titan Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Titan Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Titan Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Titan Pharmaceuticals's Shiller PE Ratio falls into.



Titan Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Titan Pharmaceuticals's E10 for the quarter that ended in Sep. 2024 is calculated as:

For example, Titan Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.83/133.0289*133.0289
=-0.830

Current CPI (Sep. 2024) = 133.0289.

Titan Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201412 -216.002 99.070 -290.043
201503 -864.007 99.621 -1,153.751
201506 -396.003 100.684 -523.220
201509 -324.003 100.392 -429.337
201512 -396.003 99.792 -527.894
201603 -324.003 100.470 -429.000
201606 1,980.020 101.688 2,590.272
201609 -432.003 101.861 -564.189
201612 -539.860 101.863 -705.037
201703 -576.005 102.862 -744.932
201706 -612.005 103.349 -787.761
201709 -720.006 104.136 -919.778
201712 -630.491 104.011 -806.390
201803 -444.004 105.290 -560.981
201806 -150.001 106.317 -187.689
201809 -408.004 106.507 -509.605
201812 -161.601 105.998 -202.812
201903 -204.002 107.251 -253.035
201906 -228.002 108.070 -280.661
201909 -108.001 108.329 -132.626
201912 -41.211 108.420 -50.565
202003 -40.600 108.902 -49.595
202006 -29.200 108.767 -35.713
202009 -30.400 109.815 -36.826
202012 -8.643 109.897 -10.462
202103 -5.600 111.754 -6.666
202106 -3.400 114.631 -3.946
202109 -3.800 115.734 -4.368
202112 -5.200 117.630 -5.881
202203 -4.800 121.301 -5.264
202206 -3.600 125.017 -3.831
202209 -3.600 125.227 -3.824
202212 -3.390 125.222 -3.601
202303 -2.230 127.348 -2.329
202306 -2.110 128.729 -2.180
202309 -0.450 129.860 -0.461
202312 -2.620 129.419 -2.693
202403 -1.240 131.776 -1.252
202406 -2.290 132.554 -2.298
202409 -0.830 133.029 -0.830

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Titan Pharmaceuticals  (NAS:TTNP) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Titan Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Titan Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Titan Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
400 Oyster Point Boulevard, Suite 505, South San Francisco, CA, USA, 94080
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
Executives
Seow Gim Shen 10 percent owner NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000
Sire Group Ltd. 10 percent owner NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000
David Natan director 11190 BISCAYNE BLVD, MIAMI FL 33181
Matthew Charles Mcmurdo director 1047 SEWARD AVE., WESTFIELD NJ 07090
Peter Louis Chasey director 3295 N. FORT APACHE ROAD, STE. 110, LAS VEGAS NV 89129
Eric Howard Greenberg director 710 CARLYLE ST, WOODMERE NY 11598
Avraham Ben-tzvi director 44 ZAYT SHEMEN ST., FLAT 4, EFRAT L3 9045544
Katherine Beebe director, officer: President and COO 400 OYSTER POINT BLVD, SUITE 505, SOUTH SAN FRANCISCO CA 94080
Choon Hau Choong 10 percent owner NO. 23 LORONG TERUBONG RIA 2,, PAYA TERUBONG, GEORGE TOWN N8 11060
David E. Lazar director, 10 percent owner, officer: Chief Executive Officer VILLA 1, 14-43RD STREET, JUMEIRAH 2, DUBAI C0 00000
Activist Investing Llc other: Member of 10% owner group 1185 AVENUE OF THE AMERICAS, 3RD FLOOR., NEW YORK NY 10036
Joseph A Akers director 630 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10111
James R Mcnab director C/O CURIS, INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Marc Rubin director, officer: Executive Chairman C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
Dane Hallberg officer: See Remarks 400 OYSTER POINT BLVD., SUITE 505, SOUTH SAN FRANCISCO CA 94080